Anti-angiogenesis inhibitors (8), PARP inhibitors (PARPis) (9), and immune checkpoint inhibitors (ICIs) (10) have shown promising results in clinical trials, with some drugs already approved for treating specific ovarian cancer subtypes. The gene discussed is PARP1; the disease is ovarian carcinoma.